148 related articles for article (PubMed ID: 35164226)
1. A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment.
Rayan M; Shadafny S; Falah A; Falah M; Abu-Lafi S; Asli S; Rayan A
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164226
[TBL] [Abstract][Full Text] [Related]
2. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy.
Sundaram S; Durairaj C; Kadam R; Kompella UB
Mol Cancer Ther; 2009 Jun; 8(6):1655-65. PubMed ID: 19509261
[TBL] [Abstract][Full Text] [Related]
3. Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence.
Nagesh PKB; Chowdhury P; Hatami E; Kumari S; Kashyap VK; Tripathi MK; Wagh S; Meibohm B; Chauhan SC; Jaggi M; Yallapu MM
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38537-38554. PubMed ID: 31553876
[TBL] [Abstract][Full Text] [Related]
4. Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model.
Mabuchi M; Ueda M; Yoshida Y; Horiike K; Yamaoka K; Nakao S; Shimizu T; Ueda Y; Tsujikawa K; Tanaka A
Anticancer Res; 2017 Apr; 37(4):1665-1676. PubMed ID: 28373427
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
[TBL] [Abstract][Full Text] [Related]
6. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Liu G; Taylor SA; Marrinan CH; Hsieh Y; Bishop WR; Kirschmeier P; Long BJ
Int J Cancer; 2009 Dec; 125(11):2711-20. PubMed ID: 19530253
[TBL] [Abstract][Full Text] [Related]
7. A Novel Paclitaxel Conjugate with Higher Efficiency and Lower Toxicity: A New Drug Candidate for Cancer Treatment.
Falah M; Rayan M; Rayan A
Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31597361
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth.
Cisse O; Quraishi M; Gulluni F; Guffanti F; Mavrommati I; Suthanthirakumaran M; Oh LCR; Schlatter JN; Sarvananthan A; Broggini M; Hirsch E; Falasca M; Maffucci T
J Exp Clin Cancer Res; 2019 Nov; 38(1):472. PubMed ID: 31752944
[TBL] [Abstract][Full Text] [Related]
9. Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance.
Haldar S; Mishra R; Billet S; Thiruvalluvan M; Placencio-Hickok VR; Madhav A; Duong F; Angara B; Agarwal P; Tighiouart M; Posadas EM; Bhowmick NA
Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8515-8523. PubMed ID: 32238563
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
Wang J; Lu Z; Wu C; Li Y; Kong Y; Zhou R; Shi K; Guo J; Li N; Liu J; Song W; Wang H; Zhu M; Xu H
Prostate; 2019 Jan; 79(1):62-72. PubMed ID: 30242862
[TBL] [Abstract][Full Text] [Related]
11. Construction and anti-tumor activities of disulfide-linked docetaxel-dihydroartemisinin nanoconjugates.
Li N; Guo W; Li Y; Zuo H; Zhang H; Wang Z; Zhao Y; Yang F; Ren G; Zhang S
Colloids Surf B Biointerfaces; 2020 Jul; 191():111018. PubMed ID: 32304917
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
Wang L; Huang X; Zheng X; Wang X; Li S; Zhang L; Yang Z
Clin Transl Oncol; 2014 Jun; 16(6):567-72. PubMed ID: 24105048
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus carrying SPAG9-shRNA enhanced the efficacy of docetaxel for advanced prostate cancer.
Lu M; Xu Z; Wei F; Wang J; Ma S; Kan Y; Li B; Wu C; Mao L
Anticancer Drugs; 2022 Feb; 33(2):142-148. PubMed ID: 34561997
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
[TBL] [Abstract][Full Text] [Related]
16. The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
Toner AP; McLaughlin F; Giles FJ; Sullivan FJ; O'Connell E; Carleton LA; Breen L; Dunne G; Gorman AM; Lewis JD; Glynn SA
Br J Cancer; 2013 Oct; 109(8):2131-41. PubMed ID: 24052043
[TBL] [Abstract][Full Text] [Related]
17. Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models.
Chen Y; Gera L; Zhang S; Li X; Yang Y; Mamouni K; Wu AY; Liu H; Kucuk O; Wu D
Cancer Lett; 2019 Apr; 446():62-72. PubMed ID: 30660650
[TBL] [Abstract][Full Text] [Related]
18. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
